ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs

ALPHAMEDIX - Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients

CLINICALTRIALS.GOV IDENTIFIER: NCT05153772

DRUG/TREATMENT:  AlphaMedix 212Pb-DOTAMTATE 

PHASE:  2

STATUS: Recruiting

SPONSOR: Radiomedix, Inc.  

COLLABORATOR: Orano Med LLC

Dr. Ebrahim Delpassand Discusses the AlphaMedix Trial (May 9, 2023)

Dr. Heloisa Soares Discusses the AlphaMedix Trial (March 10, 2023)

UPDATE

October 8, 2025: Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors

Sanofi reported that its experimental drug AlphaMedix™ (²¹²Pb-DOTAMTATE) met all its main goals in a phase 2 clinical trial, showing real benefits in people with certain gastro-pancreatic neuroendocrine tumors, whether or not they have had prior radiation treatment. The drug was generally well tolerated, and these results will inform future talks with regulators as Sanofi works toward potential approval. 

Read the full press release >>>

DESCRIPTION:

Radiomedix is sponsoring a multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive). 

In this open-label, multicenter, single-arm Phase 2 study, adult subjects with histologically confirmed NETs and positive somatostatin analog imaging, with no prior PRRT (PRRT naive) will be enrolled to receive 212Pb-DOTAMTATE.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

Susan Cork

EMAIL: scork@exceldiagnostics.com

PHONE: 713-341-3203